Coya Therapeutics plans to extend treatment beyond 48 weeks for eligible ALSTARS participants receiving COYA 302 for amyotrophic lateral sclerosis. The decision follows completion of targeted enrollment, while randomized efficacy results remain expected in early 2027 and a separate frontotemporal dementia study has been delayed.
Alchemab Therapeutics secures £25 million to double its antibody data and advance two wholly owned programs toward clinical development.
Read how AL-S Pharma’s AP-101 Phase 2 data strengthen the misfolded SOD1 case in ALS and what its Phase 3 trial must prove.
Read how Shionogi’s NeuroBANK partnership could shape Radicava evidence, ALS trial design and real-world treatment research.
Coya Therapeutics’ COYA 302 fast track status raises the stakes for Treg-based ALS therapy. Find out what comes next.
Can biomarker-driven approvals transform ALS drug development? Explore how Clene Inc.’s FDA feedback on CNM-Au8 could accelerate innovation.
A failed ALS endpoint meets a striking survival signal. Corcept now faces the harder test: proving dazucorilant in Phase 3.
Celosia Therapeutics has dosed the first ALS patient with CTx1000. Read why this TDP-43 gene therapy trial could reshape the ALS pipeline.
QurAlis ANQUR trial data puts STATHMIN-2 restoration on the ALS map. Find out what changes and what risks remain.
Coya Therapeutics expands its ALS trial for COYA 302 to Canada after Health Canada clearance. Explore what this means for the biotech’s immunotherapy platform.